Adams, C. E., Fenton, M. K. P., Quaraishi, S., et al (2001) Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry, 179, 290–299.
Barnes, T. R. E. (1989) A rating scale for drug induced akathisia. British Journal of Psychiatry, 154, 672–679.
Buchanan, A. (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychological Medicine, 22, 787–797.
Cookson, J. C. (1991) Side effects during long-term treatment with depot anti-psychotic medication. Clinical Neuropharmacology, 14, S24–S32.
Cuesta, M. J., Peralta, V. & Zarzuela, A. (2000) Re appraising insight in psychosis: multiscale longitudinal study. British Journal of Psychiatry, 177, 233–240.
David, A. (1990) Insight and psychosis. British Journal of Psychiatry, 156, 798–808.
Desai, N. M., Huq, Z., Martin, S. D., et al (1999) Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment and Assessment Group. Advances in Therapy, 16, 78–88.
Fenton, W. S., Blyler, C. R. & Heinssen, R. K. (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin, 23, 637–651.
Garavan, J., Browne, S., Gervin, M., et al (1998) Compliance with neuroleptic medication in outpatients with schizophrenia; Relationship to subjective response to neuroleptics; attitudes to medication and insight. Comprehensive Psychiatry, 39, 215–219.
Guy, W. & Ban, T. A. (1979) The AMDP System. Springer.
Haywood, T.W., Kravitz, H. M., Grossman, L. S., et al (1995) Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. American Journal of Psychiatry, 152, 856–861.
Lehman, A.F. & Steinwachs, D. M. (1998) Translating Research Into Practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations. Schizophrenia Bulletin, 24, 1–10.
McEvoy, J. P., Applebaum, P. S., Apperson, L. J., et al (1989a) Why must some schizophrenic patients be involuntarily committed? The role of insight. Comprehensive Psychiatry, 30, 13–17.
McEvoy, J. P., Apperson, L. G., Applebaum, P. S., et al (1989b) Insight in schizophrenia: Its relation to acute psychopathology. Journal of Nervous and Mental Disease, 177, 43–47.
McEvoy, J. P., Hogart, G. E. & Steingard, S. (1991) Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48, 739–745.
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Report, 10, 799–812.
Patel, M.X. & David, A.S. (2005) Why aren't depot antipsychotics prescribed more often and what can be done about it?
Advances in Psychiatric Treatment, 11, 203–213.
Sanz, M., Constable, G., Lopezibor, I., et al (1998) A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychological Medicine, 28, 437–446.
Valenstein, M., Copeland, L. A., Owen, R., et al (2001) Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. Journal of Clinical Psychiatry, 62, 545–551.
Williams, C. C. & Collins, A. (2002) Factors associated with insight among outpatients with serious mental illness. Psychiatric Services, 53, 96–98.
Woods, S.W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry, 64, 663–667.
World Health Organization (1973) Report of the International Pilot of Schizophrenia (Vol. 1). WHO.
World Health Organization (1992) The ICD–10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines.